Background: Chronic kidney disease (CKD) also called chronic renal failure is a syndrome defined as structural and /or functional abnormality of the kidney. Nicotinamide (NAM) is the amide form of vitamin B3, which is a water soluble vitamin. It can be synthesized in the body through metabolism of tryptophan or obtained from diet from either plant or animal sources. Objective: Review of the literature on nicotinamide role among kidney disease. Methods: We looked for data on Nicotinamide and kidney disease in medical journals and databases like PubMed, Google Scholar, and Science Direct. However, only the most recent or extensive study was taken into account between September 2005 and September 2022. References from related works were also evaluated by the writers. There are not enough resources to translate documents into languages other than English, hence those documents have been ignored. It was generally agreed that documents such as unpublished manuscripts, oral presentations, conference abstracts, and dissertations did not qualify as legitimate scientific study. Conclusion: NAM and its precursor NAD+ are cosubstrates for multiple regulatory proteins that improve various metabolic dysfunctions including kidney disease and extend cellular life span. Because the kidney is such a metabolically active organ, NAD and its metabolites play a crucial role in the pathogenesis, progression, and treatment of kidney disease. Sirtuins (SIRT1 and SIRT3), which are NAD+ dependent deacetylases proteins activation and PARP inhibition mediated by NAM administration may prevent and decrease progression of CKD